Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Small Cap

What’s Going On With Cancer-Focused Replimune Stock Today?

By Vandana Singh
December 5, 9:49 AM
Replimune Group Inc (NASDAQ: REPL) announced results from the primary analysis of the CERPASS trial evaluating RP1 in combination with cemiplimab for locally advanced or metastatic cutaneous 

REPL

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • Equities
  • General
  • Health Care
  • Markets
  • News
  • Reiteration
  • Trading Ideas

CRISPR Therapeutics’ Gene-Edited Oncology Pipeline To Focus On Expanded Use In Autoimmune Diseases

By Vandana Singh
December 5, 9:47 AM
Monday, CRISPR Therapeutics AG (NASDAQ: CRSP) provided an update on its immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic chimeric antigen receptor (CAR) T 

CRSP

Read More
2 minute read
  • Biotech
  • General
  • News

National Employer Selects Dario Cardiometabolic And GLP-1 Solutions To Improve Employee Health

By Benzinga Newsdesk
December 5, 9:40 AM
New client will use Dario's integrated approach to support long-term behavior change for employees living with diabetes, pre-diabetes, hypertension and those taking a GLP-1 medicationNEW YORK, Dec. 5, 2023 /PRNewswire/

DRIO

Read More
2 minute read
  • Biotech
  • General
  • Global
  • News

Artelo Biosciences Presents New Preclinical Data On ART12.11 At The 4th Annual Med-Cannabis 2023 Conference In Germany

By Benzinga Newsdesk
December 5, 9:36 AM
Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological

ARTL

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Roche’s Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation

By Vandana Singh
December 5, 9:30 AM
Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance) and fulvestrant as a potenti

RHHBF

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

Investor Demand for Clarity Grows Amid Sanofi’s Strategic R&D Shift

By Vandana Singh
December 5, 9:28 AM
Sanofi SA's (NASDAQ: SNY) CEO, Paul Hudson, is confronting mounting investor pressure as shareholders seek concrete details about the company's expanded R&D budget. 

SNY

Read More
4 minute read
  • Biotech
  • General
  • News

Results Of Three Investigator-Initiated Trials On Cadonilimab For G/GEJC, pMMR/MSS mCRC, And HCC Neoadjuvant Therapy Published At ESMO Asia 2023

By Benzinga Newsdesk
December 5, 9:16 AM
First-line therapy for gastric cancer and metastatic colorectal cancer, neoadjuvant therapy for hepatocellular carcinomaHONGKONG, Dec. 5, 2023  /PRNewswire/ -- Akeso (9926.HK) published results from three

LNVGY

Read More
2 minute read
  • Biotech
  • General
  • News

BioAtla Presented Phase 2 Clinical Trial Data At The IASLC 2023 North America Conference On Lung Cancer And Virtual KOL Event

By Benzinga Newsdesk
December 5, 9:07 AM
Results from the Phase 2 BA3011 clinical non-small cell lung cancer (NSCLC) study demonstrated promising clinical benefits in heavily pre-treated non-squamous histology patients across key endpoints BA3011 is a

BCAB

Read More
2 minute read
  • Biotech
  • General
  • News

NeoGenomics To Present New Data At San Antonio Breast Cancer Symposium Highlighting Utility Of RaDaR For Therapy Response

By Benzinga Newsdesk
December 5, 9:04 AM
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today announced new data highlighting its RaDaR® assay for minimal residual disease (MRD) will be presented at the 46th annual San Antonio

NEO

Read More
1 minute read
  • Biotech
  • General
  • News

Curis Enters Into Agreement For Emavusertib / Pembrolizumab Combination Study In Melanoma

By Benzinga Newsdesk
December 5, 9:02 AM
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into an

CRIS

Posts pagination

Previous 1 … 179 180 181 … 795 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service